Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR.

Nat Med. 2015 Nov;21(11):1318-25. doi: 10.1038/nm.3954. Epub 2015 Oct 19.

PMID:
26479923
2.

Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.

Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J.

Clin Cancer Res. 2010 Mar 1;16(5):1452-65. doi: 10.1158/1078-0432.CCR-09-2455. Epub 2010 Feb 23.

3.

Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?

Merk J, Rolff J, Becker M, Leschber G, Fichtner I.

Eur J Cardiothorac Surg. 2009 Sep;36(3):454-9. doi: 10.1016/j.ejcts.2009.03.054. Epub 2009 Jun 6.

PMID:
19502076
4.

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.

Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME.

Clin Cancer Res. 2006 Mar 1;12(5):1606-14.

5.
6.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonnet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V.

Cancer Res. 2015 Apr 15;75(8):1560-6. doi: 10.1158/0008-5472.CAN-14-1590. Epub 2015 Feb 24.

7.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

8.

Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

Merk J, Rolff J, Dorn C, Leschber G, Fichtner I.

Eur J Cardiothorac Surg. 2011 Jul;40(1):e29-33. doi: 10.1016/j.ejcts.2011.02.010. Epub 2011 Mar 21.

PMID:
21420313
9.

Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.

Calles A, Rubio-Viqueira B, Hidalgo M.

Curr Protoc Pharmacol. 2013 Jun;Chapter 14:Unit 14.26. doi: 10.1002/0471141755.ph1426s61.

PMID:
23744711
10.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET.

Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.

11.

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.

O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9. Epub 2008 Feb 27.

PMID:
18301895
12.

Patient-derived tumor xenograft models for melanoma drug discovery.

Harris AL, Joseph RW, Copland JA.

Expert Opin Drug Discov. 2016 Sep;11(9):895-906. doi: 10.1080/17460441.2016.1216968. Review.

PMID:
27454070
13.

Modeling of Patient-Derived Xenografts in Colorectal Cancer.

Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S.

Mol Cancer Ther. 2017 Jul;16(7):1435-1442. doi: 10.1158/1535-7163.MCT-16-0721. Epub 2017 May 3.

14.

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.

Clin Cancer Res. 2001 May;7(5):1429-37.

15.

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.

Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB.

Cancer Biol Ther. 2012 Jul;13(9):812-21. Epub 2012 Jun 6.

PMID:
22669574
16.

Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.

Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N, Fujiwara T.

Int J Cancer. 2006 Jul 15;119(2):432-40.

17.

Patient-derived tumour xenografts as models for breast cancer drug development.

Marangoni E, Poupon MF.

Curr Opin Oncol. 2014 Nov;26(6):556-61. doi: 10.1097/CCO.0000000000000133. Review.

PMID:
25188472
18.

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.

Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR.

Clin Cancer Res. 2012 Dec 15;18(24):6658-67. doi: 10.1158/1078-0432.CCR-12-2694. Epub 2012 Oct 18. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added].

19.

[Preclinical screening of chemotherapeutic and endocrine agents using human tumor xenografts--nude mouse system].

Kubota T, Ishibiki K, Abe O.

Gan To Kagaku Ryoho. 1991 Jul;18(9):1439-47. Japanese.

PMID:
1854214
20.

Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.

Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S, Wang Y.

Clin Cancer Res. 2010 Mar 1;16(5):1442-51. doi: 10.1158/1078-0432.CCR-09-2878. Epub 2010 Feb 23.

Supplemental Content

Support Center